- Home
- LEGH vs CRMD Comparison
LEGH vs CRMD Comparison
Compare LEGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- CRMD
- Stock Information
- Founded
- LEGH 2005
- CRMD 2006
- Country
- LEGH United States
- CRMD United States
- Employees
- LEGH N/A
- CRMD N/A
- Industry
- LEGH Homebuilding
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- CRMD Health Care
- Exchange
- LEGH Nasdaq
- CRMD Nasdaq
- Market Cap
- LEGH 588.8M
- CRMD 877.5M
- IPO Year
- LEGH 2018
- CRMD 2010
- Fundamental
- Price
- LEGH $23.49
- CRMD $11.28
- Analyst Decision
- LEGH Strong Buy
- CRMD Strong Buy
- Analyst Count
- LEGH 2
- CRMD 7
- Target Price
- LEGH $29.00
- CRMD $17.33
- AVG Volume (30 Days)
- LEGH 102.7K
- CRMD 2.3M
- Earning Date
- LEGH 08-07-2025
- CRMD 08-13-2025
- Dividend Yield
- LEGH N/A
- CRMD N/A
- EPS Growth
- LEGH 8.04
- CRMD N/A
- EPS
- LEGH 2.29
- CRMD 0.28
- Revenue
- LEGH $176,618,000.00
- CRMD $82,553,827.00
- Revenue This Year
- LEGH N/A
- CRMD $238.38
- Revenue Next Year
- LEGH $8.23
- CRMD $53.52
- P/E Ratio
- LEGH $10.24
- CRMD $40.42
- Revenue Growth
- LEGH N/A
- CRMD N/A
- 52 Week Low
- LEGH $21.58
- CRMD $3.61
- 52 Week High
- LEGH $29.31
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- LEGH 55.84
- CRMD 39.54
- Support Level
- LEGH $23.25
- CRMD $11.13
- Resistance Level
- LEGH $24.20
- CRMD $11.86
- Average True Range (ATR)
- LEGH 0.66
- CRMD 0.65
- MACD
- LEGH 0.14
- CRMD -0.34
- Stochastic Oscillator
- LEGH 69.87
- CRMD 3.81
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.